National decision-making for the introduction of new vaccines: A systematic review, 2010–2020

Donadel, Morgane; Panero, Maria S.; Ametewee, Lynnette; Shefer, Abigail

doi:10.1016/j.vaccine.2021.02.059

Cited by 30 publications

(26 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While stated preferences may not directly translate into policy recommendations or actual procurements, combined with NGRV cost effectiveness analyses and demand forecasting our study results can inform future NGRV development work. Our hope is that vaccine developers, funding agencies, and policy makers utilize results presented here to improve alignment between LMIC needs and vaccine development [39] , [40] and to reduce risk in new vaccine investments [41] , [42] .…”

Section: Discussionmentioning

confidence: 97%

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

Price

Mooney

Bain

et al. 2022

Vaccine

View full text Add to dashboard Cite

Highlights An effective and affordable injectable rotavirus vaccine may be attractive to LMICs. Co-administering oral and injectable vaccines is acceptable to many stakeholders. Oral vaccine with a birth dose is favored over a higher cost, standalone injectable. Providing rotavirus vaccine in a DTP combination is the most preferred option.

show abstract

Section: Discussionmentioning

confidence: 97%

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

Price

Mooney

Bain

et al. 2022

Vaccine

View full text Add to dashboard Cite

show abstract

“…In conclusion, depending on the specific use cases and attributes, there appears to be a compelling public health value proposition for the development and introduction of iNGRVs for young infants. This iNGRV value proposition thus adds to a growing body of work on national prioritization and decision-making for new vaccine introductions [37] as well as to efforts to ensure that products brought to market respond to LMIC needs [4].…”

Section: Discussionmentioning

confidence: 99%

Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines

Hausdorff

Price

Debellut³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Routine infant immunization with live, oral rotavirus vaccines (LORVs) has had a major impact on severe gastroenteritis disease. Nevertheless, in high morbidity and mortality settings rotavirus remains an important cause of disease, partly attributable to the sub-optimal clinical efficacy of LORVs in those settings. Regardless of the precise immunological mechanism(s) underlying the diminished efficacy, the introduction of injectable next-generation rotavirus vaccines (iNGRV), currently in clinical development, could offer a potent remedy. In addition to the potential for greater clinical efficacy, precisely how iNGRVs are delivered (multiple doses to young infants; alongside LORVs or as a booster; co-formulated with Diphtheria-Tetanus-Pertussis (DTP)-containing vaccines), their pricing, and their storage and cold chain characteristics could each have major implications on the resultant health outcomes, on cost-effectiveness as well as on product preferences by national stakeholders and healthcare providers. To better understand these implications, we critically assessed whether there is a compelling public health value proposition for iNGRVs based on potential (but still hypothetical) vaccine profiles. Our results suggest that the answer is highly dependent on the specific use cases and potential attributes of such novel vaccines. Notably, co-formulation of iNGRVs with similar or greater efficacy than LORVs with a DTP-containing vaccine, such as DTP-Hib-HepB, scored especially high on potential impact, cost-effectiveness, and strength of preference by national stakeholders and health care providers in lower and middle income countries.

show abstract

“…We structured the tool along the two lines of decision-making and implementation. The foundation for item generation was set up based on (1) a published systematic review of 116 studies on national decision-making for the introduction of new vaccines and (2) WHO guidance on principles and considerations for adding a vaccine to a national immunization program ( 28 , 30 ). Next, items in the item pool were linked to this foundation.…”

Section: Methodsmentioning

confidence: 99%

“…First are readiness assessment tools for COVID-19 vaccine introduction, which might be though inapplicable for non-pandemic vaccines, given the special priority of resources for COVID-19 ( 26 , 27 ). Second, a majority of guidelines and publications focus on vaccination of the general populations ( 28 , 29 ), or specifically for children ( 30 ) or during pregnancy ( 31 ). Despite immunization programmes' common aspects, those of aging population have specific requirements including a need for adult vaccine working groups ( 22 ), evidence on potential gains from immunization, and relevant infrastructure to deliver immunization service to this population ( 20 ).…”

Section: Introductionmentioning

confidence: 99%

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe

Pham

Beck²,

Postma³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

ObjectivesDelaying of policies for immunization of aging adults, low vaccine uptake, and the lack of supportive evidence at the national level could diminish the value in health and economics of such programs. This study aims to develop a “country score tool” to assess readiness and to facilitate evidence generation for aging adult immunization programs in Europe, and examine the comprehensiveness, relevance, acceptability, and feasibility of the tool.MethodsThe tool was developed in two phases. First, a modified Delphi process was used to construct the tool. The process included a literature review, stakeholder consultations, and a three-round Delphi study. The Delphi panel included researchers, supra-national and national decision-makers of immunization programs recruited from five countries, using snowball sampling method. The consensus was predefined at the agreement rate of 70%. Pilot testing of the tool was conducted in the Netherlands, Germany, Serbia, and Hungary involving researchers in the field of health technology assessment. After assessing the countries' readiness, researchers evaluated four features, namely comprehensiveness, relevance, acceptability, and feasibility of the tool via an online survey that included 5-scale Likert questions. The percentages of affirmative answers including “agree” and “totally agree” choices were presented.ResultsThe review identified 16 tools and frameworks that formed the first version of our tool with 14 items. Eight experts were involved in the Delphi panel. Through three Delphi rounds, four items were added, one was dropped, and all others were amended. The consensus was achieved on the tool with 17 items divided into decision-making and implementation parts. Each item has a guiding question, corresponding to explanations and rationales to inform assessment with readiness scores. Eight researchers completed the pilot testing. The tool was rated as comprehensive (75%), relevant (100%), acceptable (75%), and feasible (88%) by participants.ConclusionThrough a thorough and transparent process, a country score tool was developed helping to identify strengths, weaknesses, and evidential requirements for decision-making and implementation of immunization programs of aging adults. The tool is relevant for different European contexts and shows good comprehensiveness, acceptability, and feasibility.

show abstract

National decision-making for the introduction of new vaccines: A systematic review, 2010–2020

Cited by 30 publications

References 127 publications

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

Does Anybody Want an Injectable Rotavirus Vaccine, and Why? Understanding the Public Health Value Proposition of Next-Generation Rotavirus Vaccines

Country score tool to assess readiness and guide evidence generation of immunization programs in aging adults in Europe

Contact Info

Product

Resources

About